STAT6-IN-1

• UNSPSC Description:

  STAT6-IN-1 (Compound 19a) is a STAT6 inhibitor with a high affinity for the SH2 domain of STAT6 (IC50=0.028 µM). STAT6-IN-1 can be used in studies of allergic lung disease, allergic rhinitis, chronic obstructive pulmonary disease or cancer[1][2][3].

• Target Antigen:

  STAT

• Type:

  Reference compound

• Related Pathways:

  JAK/STAT Signaling;Stem Cell/Wnt

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Cancer; Inflammation/Immunology

• Assay Protocol:

  https://www.medchemexpress.com/stat6-in-1.html

• Solubility:

  DMSO : 100 mg/mL (ultrasonic)

• Smiles:

  O=C([C@H]1N(CCC1)C([C@H](C(C)(C)C)NC(/C=C(C2=CC=C(C=C2)OP(O)(O)=O)\C)=O)=O)N(C3=CC=CC=C3)C4=CC=C(C=C4)I

• Molecular Weight:

  745.54

• References & Citations:

  [1]Mandal PK, et al. Targeting the Src Homology 2 (SH2) Domain of Signal Transducer and Activator of Transcription 6 (STAT6) with Cell-Permeable, Phosphatase-Stable Phosphopeptide Mimics Potently Inhibits Tyr641 Phosphorylation and Transcriptional Activity. J Med Chem. 2015 Nov 25;58(22):8970-84. |[2]John S, et al. Stat6 inhibitors. Patent WO2014182928A2. |[3]Zhang F, et al. Ultrasound-triggered biomimetic ultrashort peptide nanofiber hydrogels promote bone regeneration by modulating macrophage and the osteogenic immune microenvironment. Bioact Mater. 2023 Aug 14;31:231-246.

• Shipping Conditions:

  Room Temperature

• Clinical Information:

  No Development Reported

• CAS Number:

  1637532-68-3